Histolix, a Sacramento, CA-based developer of direct-to-digital read pathology solutions, received a $3.2M grant from the National Cancer Institute (NCI).
The latest grant brings the total of funding awarded to the Histolix founding team to $9 million from the NCI and National Institute of Health (NIH) over the past 12 months.
The company intends to use the funds for further evaluation of its Giga Fluorescence Imitating Brightfield Imaging (FIBI).
Led by CEO Rob Royea, CSO Richard Levenson, MD and CTO Farzad Fereidouni, PhD, Histolix provides a digital slide-free histopathology solution that is deployable in both pathology labs as well as clinician-focused point-of-care settings. In coordination with the founding team, Histolix recently concluded a 100-tissue sample equivalency validation study across multiple tissue types, resulting in no major discordance with conventional FFPE pathology standards.
It has licensed its patented “direct read” technology from University of California, Davis.
The investigative team is also comprised of healthcare researchers Alexander “Sandy” Borowsky, MD; Candice Sauder, MD and Diana Miglioretti, PhD.
FinSMEs
30/06/2023